Allena Pharmaceuticals Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Allena Pharmaceuticals Inc ALNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.14 04:52:13
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
1.13 1.20 0.07 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.14 USD

Allena Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 65.68M 57.61M 53.66M $ - $ - -1.03 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 74.00k 7.10%

more financials information »

Allena Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.,0700.054.59%
1 Month1.101.341.021.17724,6520.043.64%
3 Months1.751.8351.021.40828,232-0.61-34.86%
6 Months1.492.781.021.691,590,894-0.35-23.49%
1 Year1.863.601.021.671,450,216-0.72-38.71%
3 Years16.2016.610.552.07591,805-15.06-92.96%
5 Years12.0017.560.552.38519,515-10.86-90.5%

Allena Pharmaceuticals Description

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Your Recent History
Allena Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.